Applied Molecular Transport

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood on November 21, 2016 and is headquartered in Menlo Park, CA.

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis

Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET (11:20 a.m. PT).

Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference

Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

Applied Molecular Transport Inc (NASDAQ: AMTI) announced Phase 2 topline results from the FILLMORE monotherapy trial for AMT-101 in chronic pouchitis. Pouchitis is inflammation in the lining of a pouch created during surgery to treat ulcerative colitis or certain other diseases.

Applied Molecular's AMT-101 Shows Favorable Clinical Activity, Safety Profile In Inflammatory Bowel Disease

–  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD) –  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile–   Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups–   Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis–   Further substantiates potential of AMT-101 and Company's oral biologics platform–   Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT)

Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Publication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company's proprietary biologic product candidates to cross intestinal epithelial barrier

Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company's Proprietary Technology Platform

Company continues to strengthen key functions and corporate leadership

Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs

Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as follows

Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET.

Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference

John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair

Applied Molecular Transport Announces Board Appointments

Management to highlight novel oral biologics technology platform, clinical programs and research activities

Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in September and October.

Applied Molecular Transport Announces Upcoming Investor Events in September and October

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly Schachner, M.D. a seasoned and accomplished industry veteran to its Board of Directors.

Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors

Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance

Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update

The stock price of Applied Molecular Transport Inc. (NASDAQ: AMTI) increased by over 20% pre-market. This is why it happened.

AMTI Stock Price Increases Over 20% Pre-Market: Why It Happened

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord Genuity's 41st Annual Growth Conference on Wednesday, August 11, 2021 at 2:30 p.m. ET.

Applied Molecular Transport to Present at Canaccord Genuity's 41st Annual Growth Conference

Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology

Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO ‘21 Virtual Congress

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 11:00 a.m. ET.

Applied Molecular Transport to Present at Jefferies Virtual Healthcare Conference

Enrollment ongoing in each of oral AMT-101's four Phase 2 trials

Applied Molecular Transport Reports First Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,875,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 375,000 additional shares of its common stock, at a public offering price of $42.00 per share. All of the shares of common stock were offered by AMT. The aggregate gross proceeds to AMT from the offering were approximately $120.8 million, before deducting underwriting discounts and commissions and other offering expenses.

Applied Molecular Transport Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

The stock price of Applied Molecular Transport Inc. (NASDAQ: AMTI) increased by 44.44% yesterday. This is why it happened.

Applied Molecular Transport Stock Price Increased 44.44%: Why It Happened

The stock price of Applied Molecular Transport (NASDAQ: AMTI) increased by over 25% during intraday trading. This is why it happened.

Applied Molecular Transport Stock Price Increased Over 25% Intraday: Why It Happened

SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $42.00 per share. All of the shares of common stock are being offered by AMT. In addition, AMT has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to AMT from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AMT, are expected to be $105.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on April 6, 2021, subject to the satisfaction of customary closing conditions.

Applied Molecular Transport Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in the proposed offering will be sold by AMT. In addition, AMT expects to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

News for Applied Molecular Transport Stock (AMTI)